Newron Pharmaceuticals S.p.A. | Income Statement
Fiscal year is January-December. All values CHF Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
3,954.50
1,578.50
2,429.10
5,162.30
14,748.80
4,647.20
SG&A Expense
13,879.60
12,888.00
21,338.10
29,443.90
24,687.10
28,744.30
EBIT
9,971.90
11,349.50
18,984.70
24,317.50
9,991.70
24,151.40
Unusual Expense
2,566.20
2,580.30
7,180.70
-
-
-
Non Operating Income/Expense
3,043.80
779.50
641.70
97.00
1,033.60
135.10
Interest Expense
-
-
-
143.90
94.40
64.70
Pretax Income
9,493.10
13,020.30
26,675.80
24,105.00
10,893.10
24,198.80
Income Tax
756.90
762.50
2,313.80
7,499.90
5,029.10
6,839.70
Consolidated Net Income
8,736.20
12,257.80
24,362.00
16,605.10
5,864.00
17,359.10
Net Income
8,736.20
12,257.80
24,362.00
16,605.10
5,864.00
17,359.10
Net Income After Extraordinaries
8,736.20
12,257.80
24,362.00
16,605.10
5,864.00
17,359.10
Net Income Available to Common
8,736.20
12,257.80
24,362.00
16,605.10
5,864.00
17,359.10
EPS (Basic)
0.76
0.97
1.77
1.13
0.36
0.97
Basic Shares Outstanding
11,508.00
12,686.00
13,722.00
14,688.00
16,300.00
17,844
EPS (Diluted)
0.76
0.97
1.78
1.13
0.36
0.97
Diluted Shares Outstanding
11,508.00
12,686.00
13,722.00
14,688.00
16,300.00
17,844
EBITDA
9,925.10
11,309.50
18,908.90
24,281.60
9,938.40
24,097.20
Non-Operating Interest Income
1.20
129.90
131.30
259.40
226.50
152.40
About Newron Pharmaceuticals
View Profile
